APA (7th ed.) Citation

Reuschenbach, M., Kloor, M., Prigge, E., Sauer, M., & Knebel Doeberitz, M. v. (2016). A phase 1/2a study to test the safety and immunogenicity of a p16INK4a peptide vaccine in patients with advanced human papillomavirus-associated cancers. Cancer, 122(9), . https://doi.org/10.1002/cncr.29925

Chicago Style (17th ed.) Citation

Reuschenbach, Miriam, Matthias Kloor, Elena-Sophie Prigge, Madeleine Sauer, and Magnus von Knebel Doeberitz. "A Phase 1/2a Study to Test the Safety and Immunogenicity of a P16INK4a Peptide Vaccine in Patients with Advanced Human Papillomavirus-associated Cancers." Cancer 122, no. 9 (2016). https://doi.org/10.1002/cncr.29925.

MLA (9th ed.) Citation

Reuschenbach, Miriam, et al. "A Phase 1/2a Study to Test the Safety and Immunogenicity of a P16INK4a Peptide Vaccine in Patients with Advanced Human Papillomavirus-associated Cancers." Cancer, vol. 122, no. 9, 2016, https://doi.org/10.1002/cncr.29925.